skinny.

Latest / Eyewire News: The Podcast

Aldeyra Resubmits NDA for DED Drug Reproxalap

Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.